Physician profile
Patrick Saitta
NPI 1760669139
$18,591.89
in general payments reported to CMS, 2019-2025
39 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,391 · 2020: $6,015 · 2021: $1,990 · 2022: $3,667 · 2023: $1,841 · 2024: $1,998 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,959 · Travel and Lodging: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,959.02 |
| Travel and Lodging | $569.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumendi LLC | $6,811.46 | 2019-2023 | Dilumen Ez1, 130 Cm, Dilumen Ez1, 103 Cm |
| Abbvie INC. | $3,454.62 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,508.55 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $938.95 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $934.62 | 2019-2025 | |
| Boston Scientific Corporation | $887.75 | 2020-2023 | Resolution 360 Clip, Orise |
| Conmed Corporation | $560.19 | 2022-2025 | Conmed Hemostasis, Conmed Biliary |
| Olympus Corporation of The Americas | $417.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $383.83 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $345.70 | 2019-2025 | Sucraid, Sucraid |
| Endogastric Solutions, INC | $256.96 | 2019-2023 | Esophyx |
| Medtronic, INC. | $206.36 | 2022 | |
| Covidien Lp | $189.24 | 2019 | |
| Phathom Pharmaceuticals, INC. | $176.50 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $157.99 | 2024-2025 | Zenpep |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Saitta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.